Literature DB >> 28578937

Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.

Claudia Mascia1, Miriam Lichtner2, Paola Zuccalà3, Serena Vita3, Tiziana Tieghi4, Raffaella Marocco4, Stefano Savinelli3, Raffaella Rossi3, Marco Iannetta3, Michela Campagna3, Francesco Schiavone5, Fabio Mengoni3, Gianluca Russo3, Claudio Maria Mastroianni4, Vincenzo Vullo3.   

Abstract

BACKGROUND AND
OBJECTIVE: Interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble (s) CD163 and sCD14 play an important role in the pathogenesis of HCV and HIV infection and are involved in inflammation and liver fibrosis. The aim of the present study was to evaluate at a single time point, plasma soluble biomarkers and inflammatory monocytes subsets in different groups of subjects: (i) HIV monoinfected patients on suppressive ART; (ii) HIV/HCV coinfected patients on ART, with undetectable HIV viremia (including either subjects who had active HCV replication or those who cleared HCV); (iii) HCV monoinfected individual with active viral replication.
METHODS: Hundred and twenty-nine plasma samples were analyzed including HCV and HIV monoinfected patients, HIV/HCV coinfected patients, with active HCV infection (AHI) or with HCV viral clearance (VHC) and healthy donors (HD). Levels of IP-10, sCD163 and sCD14 were measured by ELISA. Absolute cell counts of monocyte subpopulations were enumerated in whole blood by using flow cytometric analyses.
RESULTS: IP-10 and sCD163 plasma levels were higher in HCV monoinfected and in AHI coinfected pts compared to HIV monoinfected and HD, whereas sCD14 levels were higher only in HIV monoinfected patients. Considering the degree of fibrosis, sCD163 and sCD14 levels positively correlated with kPa values (as assessed by fibroscan) and FIB-4 in HCV monoinfected group. On the other hand, IP-10 did not correlate with the fibrosis stage and it was found increased also in patients with low fibrosis. Moreover, we found an increase of the inflammatory NCM subset, in non-cirrhotic HCV subjects, while no alterations were observed in HIV, AHI and VHC.
CONCLUSIONS: Our study suggests a scenario in which active HCV infection is associated with a strong pro-inflammatory state, even in the initial stage of liver fibrosis, regardless the presence of HIV coinfection, thus underlying the need of an early anti-HCV treatment.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Hepatitis C virus (HCV); Human immunodeficiency virus (HIV); IP-10; Monocyte subsets; sCD14; sCD163

Mesh:

Substances:

Year:  2017        PMID: 28578937     DOI: 10.1016/j.clinre.2017.04.007

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  13 in total

1.  Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.

Authors:  Saverio G Parisi; Samantha Andreis; Carlo Mengoli; Nicola Menegotto; Silvia Cavinato; Renzo Scaggiante; Massimo Andreoni; Giorgio Palù; Monica Basso; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2018-03-09       Impact factor: 3.402

2.  The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.

Authors:  Victoria Cairoli; Elena De Matteo; Paola Casciato; Beatriz Ameigeiras; María Victoria Preciado; Pamela Valva
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

3.  HIV Infection, HCV Coinfection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation.

Authors:  Mollie A Monnig; Ronald Cohen; Bharat Ramratnam; Mikayla McAdams; Karen Tashima; Peter M Monti
Journal:  Alcohol Clin Exp Res       Date:  2019-04-29       Impact factor: 3.455

4.  Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

Authors:  Carey L Shive; Chelsey J Judge; Brian Clagett; Robert C Kalayjian; Melissa Osborn; Kenneth E Sherman; Carl Fichtenbaum; Rajesh T Gandhi; Minhee Kang; Daniel L Popkin; Scott F Sieg; Michael M Lederman; Benigno Rodriguez; Donald D Anthony
Journal:  Vaccine       Date:  2017-12-16       Impact factor: 4.169

5.  Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients.

Authors:  Raffaella Marocco; Anna Carraro; Maria Antonella Zingaropoli; Parni Nijhawan; Eeva Tortellini; Mariasilvia Guardiani; Fabio Mengoni; Paola Zuccalà; Valeria Belvisi; Blerta Kertusha; Alberico Parente; Cosmo Del Borgo; Vincenzo Vullo; Maria Rosa Ciardi; Claudio Maria Mastroianni; Miriam Lichtner
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 7.561

6.  Persistent high plasma levels of sCD163 and sCD14 in adult patients with measles virus infection.

Authors:  Claudia Mascia; Irene Pozzetto; Blerta Kertusha; Raffaella Marocco; Cosmo Del Borgo; Tiziana Tieghi; Serena Vita; Stefano Savinelli; Marco Iannetta; Vincenzo Vullo; Miriam Lichtner; Claudio Maria Mastroianni
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

7.  Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort).

Authors:  Issifou Yaya; Fabienne Marcellin; Marie Costa; Philippe Morlat; Camelia Protopopescu; Gilles Pialoux; Melina Erica Santos; Linda Wittkop; Laure Esterle; Anne Gervais; Philippe Sogni; Dominique Salmon-Ceron; Maria Patrizia Carrieri
Journal:  Nutrients       Date:  2018-05-31       Impact factor: 5.717

8.  Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.

Authors:  Jean-Baptiste Gorin; David F G Malone; Benedikt Strunz; Tony Carlsson; Soo Aleman; Niklas K Björkström; Karolin Falconer; Johan K Sandberg
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379

9.  Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection.

Authors:  Serena Vita; Paola Zuccalà; Stefano Savinelli; Claudia Mascia; Raffaella Rossi; Francesco Schiavone; Raffaella Marocco; Tiziana Tieghi; Marco Iannetta; Parni Nijhawan; Maria Antonella Zingaropoli; Gabriella d'Ettore; Vincenzo Vullo; Claudio Maria Mastroianni; Miriam Lichtner
Journal:  J Immunol Res       Date:  2020-03-16       Impact factor: 4.818

Review 10.  Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review.

Authors:  Ahmed Babiker; Mohamed Hassan; Safwan Muhammed; Gregory Taylor; Bhawna Poonia; Anoop Shah; Shashwatee Bagchi
Journal:  Clin Cardiol       Date:  2019-11-30       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.